# PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

> **NCT07670650** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Florida** · enrollment: 108 (estimated)

## Conditions studied

- Type 1 Diabetes (T1D)

## Interventions

- **DRUG:** SAB-142
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07670650
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670650, "PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*